Skip to main content
Livermore
Livermore
ZHEN

Neurocrine Biosciences Inc

NBIX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000914475

In the last 90 days, Neurocrine Biosciences Inc insiders filed 0 open-market purchases and 7 sales; 782 institutions reported holding it in 13F filings for Q2 2026, worth $17.0B in total; no superinvestor holds it.

Holders of 5% or more of NBIX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Neurocrine Biosciences Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of NBIX
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A12.10%12.1M shares–Apr 28, 20251 filingApr 28, 2025SEC
JPMorgan Chase & Co13G/A6.30%6.34M shares+1.10 ppfrom 5.20%Jan 21, 20262 filingsJul 27, 2026SEC
Dodge & Cox13G5.60%5.53M sharesNewMay 14, 20251 filingMay 14, 2025SEC
Vanguard Capital Management LLC13G5.23%5.26M sharesNewApr 30, 20261 filingApr 30, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

27 Schedule 13D and 13G filings on Neurocrine Biosciences Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on NBIX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 27, 202611:17 AM ETJPMorgan Chase & Co13G/A6.30%6.34M shares+1.10 ppfrom 5.20%Jun 30, 2026SEC
Apr 30, 202611:41 AM ETVanguard Capital Management LLC13G5.23%5.26M sharesNewMar 31, 2026SEC
Mar 27, 202610:50 AM ETVanguard Group Inc13G/A0.00%0 shares−10.15 ppfrom 10.15%Below 5%Mar 13, 2026SEC
Jan 21, 20268:13 AM ETJPMorgan Chase & Co13G5.20%5.20M sharesNewDec 31, 2025SEC
May 14, 20254:24 PM ETDodge & Cox13G5.60%5.53M sharesNewMar 31, 2025SEC
Apr 28, 20257:42 AM ETBlackRock, Inc.13G/A12.10%12.1M shares–Mar 31, 2025SEC
Mar 6, 20252:09 PM ETVanguard Group Inc13G/A10.15%10.1M shares–Feb 28, 2025SEC
Feb 5, 20256:50 AM ETState Street Corp13G4.80%4.89M shares–Below 5%Dec 31, 2024SEC
Oct 17, 2024State Street Corp13GOld format–New–SEC
Feb 13, 2024Vanguard Group Inc13G/AOld format–––SEC
Jan 23, 202411:52 AM ETBlackRock Inc.13G/AOld format–––SEC
Feb 9, 2023Janus Henderson Group PLC13G/AOld format–––SEC
Feb 9, 2023Vanguard Group Inc13G/AOld format–––SEC
Jan 23, 20233:52 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 14, 2022Price T Rowe Associates Inc13G/AOld format–––SEC
Feb 10, 2022Janus Henderson Group PLC13G/AOld format–––SEC
Feb 10, 2022Vanguard Group Inc13G/AOld format–––SEC
Jan 27, 20221:59 PM ETBlackRock Inc.13G/AOld format–––SEC
Jan 25, 20226:45 PM ETBlackRock Inc.13G/AOld format–––SEC
Aug 10, 2021FMR LLC13G/AOld format–––SEC
Apr 12, 2021Janus Henderson Group PLC13G/AOld format–––SEC
Apr 9, 20216:00 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 16, 2021Capital International Investors13G/AOld format–––SEC
Feb 16, 2021Price T Rowe Associates Inc13G/AOld format–––SEC
Feb 11, 2021Janus Henderson Group PLC13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Feb 8, 2021FMR LLC13G/AOld format–––SEC
Jan 29, 20215:23 PM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Neurocrine Biosciences Inc shares.

No Form 144 notices for Neurocrine Biosciences Inc are on file.